Verition Fund Management
One American LaneGreenwich, CT 06831-9998
Website: veritionfund.com
Firm Size
- Assets Under Management (AUM):$107.3 Billion
- Number of Funds:4
- Employees:524
- Firm Type:Hedge Fund
Description
Verition Fund Management LLC is an investment management firm based in Greenwich, Connecticut. It specializes in quantitative trading strategies and alternative investments. The company was founded in 2008 and has since grown to manage a portfolio of assets across various asset classes, including equities, fixed income, commodities, and currencies. Verition's investment approach incorporates advanced modeling techniques and data analysis to identify and exploit market inefficiencies. They employ a variety of strategies, including statistical arbitrage, volatility trading, and systematic trend-following, to generate returns for their clients. The firm emphasizes rigorous research and risk management in order to maintain consistent performance. As of now, Verition Fund Management LLC has an experienced team of professionals with expertise in quantitative finance, computer science, and mathematics. They leverage proprietary technology platforms and algorithms to execute trades quickly and efficiently. The firm handles both proprietary trading and manages funds on behalf of institutional and high-net-worth clients. GREENWICH CT, which is home to many financial firms, provides an advantageous location for Verition. Situated in close proximity to Wall Street and other major financial centers, the firm benefits from the access to industry talent and resources. Additionally, the area's robust infrastructure and regulatory environment support Verition's operations. Overall, Verition Fund Management LLC stands out for its specialization in quantitative trading strategies and the use of advanced technology to generate returns. With its experienced team, rigorous research, and risk management, the firm aims to deliver consistent performance and meet the investment objectives of its clients.Latest News
Powered by
Jun 28, 2023: Evommune Adds Additional Investment In Series B Financing And Bolsters Leadership Team
Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, today announced the closing of an additional $7.5 million to its Series B financing from new investor Verition Fund Management, bringing the total raised in the Series B round to $57.5 million . The company previously announced the closing of the initial $50 million in April 2023 . In addition, the company also announced the appointment of J. Mark Jackson , MD, as Vice President, Clinical Development.